What is Relmada Therapeutics, Inc.'s change in prepaids?

Relmada Therapeutics, Inc. (RLMD) reported change in prepaids of $402.43K in Q1 2026.

How has Relmada Therapeutics, Inc.'s change in prepaids changed year-over-year?

Relmada Therapeutics, Inc.'s change in prepaids increased by 238.7% year-over-year, from -$290.05K to $402.43K.

Nuvation BioNUVB

$4.44M+288%

XER

Xeris Biopharma Holdings, Inc.XERS

-$145K+90.5%

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s change in prepaids?: Relmada Therapeutics, Inc. (RLMD) reported change in prepaids of $402.43K in Q1 2026.
How has Relmada Therapeutics, Inc.'s change in prepaids changed year-over-year?: Relmada Therapeutics, Inc.'s change in prepaids increased by 238.7% year-over-year, from -$290.05K to $402.43K.